lorcaserin: Clinical Trials

8 trials of lorcaserin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 3 terminated. 8 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 38Completed 5, Terminated 3
Phase 22Completed 1, Terminated 1

Follow lorcaserin: new trials by email Literature Review of lorcaserin trials Research Report on lorcaserin

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
Placebo, Lorcaserin - Epilepsies, Myoclonic
Phase 3TerminatedEisai Inc.222020-09-232025-10-08
Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients
Lorcaserin 10 mg BID, Matching Placebo BID - Obesity
Phase 3TerminatedKanion & Huawe Medicine Co.,Ltd1002019-09-172022-05-02
Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
Lorcaserin, Placebo - Opioid-use Disorder
Phase 2 / Phase 3CompletedNew York State Psychiatric Institute602017-05-252020-10-05
Addressing Post Cessation Weight Gain
lorcaserin, Varenicline, Placebo - Obesity, Smoking Cessation
Phase 2 / Phase 3TerminatedMayo Clinic842016-06-152021-06-10
Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management
LLLT, Lorcaserin - Overweight, Obese
Phase 3CompletedMayo Clinic442014-06-012016-11-22
BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo - Obesity
Phase 3CompletedEisai Inc.40082008-01-012019-10-04
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID), Matching Placebo - Obesity
Phase 3CompletedEisai Inc.6042007-12-012019-10-02
BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management
Lorcaserin 10 mg BID, Matching Placebo BID - Obesity
Phase 3CompletedEisai Inc.31822006-11-012019-10-02

Conditions studied

Obesity (6)  ·  Cardiovascular Diseases (3)  ·  Dyslipidemias (3)  ·  Hypertension (3)  ·  Sleep Apnea Syndromes (3)  ·  Weight Loss (3)  ·  Overweight (2)  ·  Epilepsies, Myoclonic (1)  ·  Epilepsy (1)  ·  Obesity, Abdominal (1)  ·  Opioid-Related Disorders (1)  ·  Seizures (1)  ·  Smoking Cessation (1)

Sponsors

Eisai Inc. (4)  ·  Mayo Clinic (2)  ·  Kanion & Huawe Medicine Co.,Ltd (1)  ·  New York State Psychiatric Institute (1)

Countries

United States (7)  ·  Canada (1)  ·  China (1)

Top investigators

Frances R Levin, MD (1)  ·  Ivana T. Croghan, PhD (1)  ·  Ryan T Hurt, MD, PhD (1)  ·  Xiaohui Guo, Ph. D (1)

Results publications

PMID 23661689, PMID 27206567, PMID 27659698, PMID 27888609, PMID 27116910, PMID 20647200, PMID 21795446, PMID 22421927, PMID 27389084, PMID 27708788, PMID 28345809, PMID 36160639

NIH funding

K23DA037299 (1)